Kolexia
Soulie Patrick
Oncologie médicale
Ico - Site Paul Papin
Angers, France
88 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Sarcomes Fatigue Tumeurs des tissus mous Récidive tumorale locale Ostéoporose Cardiopathies Tumeurs de l'utérus

Industries

Novartis
3 collaboration(s)
Dernière en 2022
Advanced Accelerator Applications
3 collaboration(s)
Dernière en 2022
Ipsen
1 collaboration(s)
Dernière en 2020
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

AcSé: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Essai Clinique (Unicancer)   26 février 2024
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Journal of the National Cancer Institute   08 septembre 2023
EPICURE_SEIN: Prediction in Silico of Overall Survival in a Pilot Prospective Cohort Study of Metastatic Breast Cancer Patients
Essai Clinique (Lilly)   31 juillet 2023
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
The Lancet. Oncology   07 juillet 2023
CANTO: A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Cancer - Breast and Lung.
Essai Clinique (Unicancer)   20 avril 2023
CHIPPI: Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Essai Clinique (Centre Oscar-Lambret)   06 décembre 2022
Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis.
Cancers   28 septembre 2022
Contraceptive Use in Premenopausal Women With Early Breast Cancer.
JAMA network open   01 septembre 2022
Factors associated with enrolment in clinical trials among women with early-stage breast cancer.
ESMO open   17 juin 2022
Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.
2022 ASCO Annual Meeting I   02 juin 2022